Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab

Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study

(2020) Lorenza Vantaggiato et al.   LUNG

Regulatory T Cells in Severe Persistent Asthma in the Era of Monoclonal Antibodies Target Therapies

(2019) L Bergantini et al.   INFLAMMATION

Oxidative stress and cellular pathways of asthma and inflammation: Therapeutic strategies and pharmacological targets

(2018) Vikas Mishra et al.   PHARMACOLOGY & THERAPEUTICS

Personalized Medicine in Allergy

(2017) Matteo Ferrando et al.   Allergy Asthma & Immunology Research

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

(2017) Geoffrey L Chupp et al.   Lancet Respiratory Medicine

Precision medicine and precision health: Building blocks to foster a revolutionary health care model

(2016) Cezmi A. Akdis et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

(2016) Eugene R Bleecker et al.   LANCET

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

(2016) J Mark FitzGerald et al.   LANCET

Clinical manifestations of asthma during combination therapy using ceruloplasmin

(2016) V. M. Provotorov et al.   TERAPEVTICHESKII ARKHIV

IgE-tailpiece associates with α-1-antitrypsin (A1AT) to protect IgE from proteolysis without compromising its ability to interact with FcεRI

(2016) Phyllis M. Quinn et al.   Scientific Reports

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma

(2015) Richard M. Nowak et al.   AMERICAN JOURNAL OF EMERGENCY MEDICINE

FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin

(2015) Michal Pyzik et al.   JOURNAL OF IMMUNOLOGY

IL-1 as a target in inflammation

(2015) Yuki Ito et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma

(2014) Elisabeth H. Bel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

(2014) Hector G. Ortega et al.   NEW ENGLAND JOURNAL OF MEDICINE

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study

(2014) Mario Castro et al.   Lancet Respiratory Medicine

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

(2013) K. F. Chung et al.   EUROPEAN RESPIRATORY JOURNAL

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

(2013) Michel Laviolette et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Identification and characterization of α1-antitrypsin in fibrin clots

(2013) S. Talens et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Airway TGF-β1 and oxidant stress in children with severe asthma: Association with airflow limitation

(2012) Sheena D. Brown et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

(2012) Ian D Pavord et al.   LANCET

Benralizumab – a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma

(2011) Aasia Ghazi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Mepolizumab in eosinophilic disorders

(2011) J Pablo Abonia et al.   Expert Review of Clinical Immunology

Molecular basis underlying the biological effects elicited by extremely low-frequency magnetic field (ELF-MF) on neuroblastoma cells

(2011) Marilisa Sulpizio et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Interleukin-1β induces ceruloplasmin and ferroportin-1 gene expression via MAP kinases and C/EBPβ, AP-1, and NF-κB activation

(2010) Tiziana Persichini et al.   NEUROSCIENCE LETTERS

Leptin and leptin receptor expression in asthma

(2009) Andreina Bruno et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

(2009) Pranabashis Haldar et al.   NEW ENGLAND JOURNAL OF MEDICINE